본문 바로가기
KERD
논문KCI 등재

2형 당뇨병 환자에서 SGLT2 억제제에 의한 요산 관련 이상반응 감소 효과: 체계적 문헌고찰 및 메타분석

SGLT2 Inhibitors Reduce Uric Acid-Related Adverse Events in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

박정규|김지혜|최혜덕|아영미|신영인
한국병원약사회 (The Korean Society of Health-System Pharmacists)|2023.11|병원약사회지 (Journal of Korean Society of Health-System Pharmacists)|제40권 제4호|pp. 423-432

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Adverse eventsUric acidType 2 diabetes mellitusSGLT2 inhibitor

초록

Background : Recent studies demonstrated that sodium glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects including the uric acid lowering effect. However, further research is needed to determine whether the uric acid reduction effect actually leads to improvement in gout or hyperuricemia. Objective : We conducted a systematic review and meta-analysis to evaluate the effect of SGLT2 inhibitors on reducing uric acid-related adverse events in patients with type 2 diabetes mellitus. Methods : We assessed the risk of uric acid-related adverse events including gout, hyperuricemia, blood uric acid increase, and urolithiasis with SGLT2 inhibitors treatment compared to controls (placebo or other hypoglycemic agents). In addition, we conducted the risk of all and serious adverse event rates. Results : Results of this meta-analysis, including 9 studies, showed that the risk of uric acid-related adverse events was significantly reduced in patients on SGLT2 inhibitors treatment than in controls (OR=0.692; 95% CI 0.560–0.856). Also, in patients on SGLT2 inhibitors treatment, the risk of serious adverse events decreased significantly (OR=0.674; 95% CI: 0.491–0.926). The risk of overall adverse events was not significantly different between the treatment and control groups. Conclusion : The results of this study showed that SGLT2 inhibitors reduce uric acid-related adverse events and serious adverse events. These results provide evidence for the safe and effective use of SGLT2 inhibitors.

Abstract

Background : Recent studies demonstrated that sodium glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects including the uric acid lowering effect. However, further research is needed to determine whether the uric acid reduction effect actually leads to improvement in gout or hyperuricemia. Objective : We conducted a systematic review and meta-analysis to evaluate the effect of SGLT2 inhibitors on reducing uric acid-related adverse events in patients with type 2 diabetes mellitus. Methods : We assessed the risk of uric acid-related adverse events including gout, hyperuricemia, blood uric acid increase, and urolithiasis with SGLT2 inhibitors treatment compared to controls (placebo or other hypoglycemic agents). In addition, we conducted the risk of all and serious adverse event rates. Results : Results of this meta-analysis, including 9 studies, showed that the risk of uric acid-related adverse events was significantly reduced in patients on SGLT2 inhibitors treatment than in controls (OR=0.692; 95% CI 0.560–0.856). Also, in patients on SGLT2 inhibitors treatment, the risk of serious adverse events decreased significantly (OR=0.674; 95% CI: 0.491–0.926). The risk of overall adverse events was not significantly different between the treatment and control groups. Conclusion : The results of this study showed that SGLT2 inhibitors reduce uric acid-related adverse events and serious adverse events. These results provide evidence for the safe and effective use of SGLT2 inhibitors.

참고문헌 (31)

  1. "Diabetes Fact Sheet in Korea 2022"[URL]
  2. Kramer CK, "Sodium-glucose cotransporter-2(SGLT-2)inhibitors and the treatment of type 2 diabetes", Annu Rev Med, 70(1), pp.323~334 (2019)
  3. Kumar K, "SGLT-2inhibitors : Ideal remedy for cardioprotection in diabetes mellitus", Curr Mol Pharmacol, 14(4), pp.487~497 (2021)
  4. 박소연, "제2형 당뇨병 환자에서 Metformin과 병용한 Sodium-Glucose Cotransporter 2 Inhibitors와 Dipeptidyl Peptidase 4 Inhibitors의 효능 비교", 병원약사회지, 37(3), pp.341~352 (2020), 한국병원약사회[DOI]
  5. Kim WJ, "The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2)Inhibitor", J Korean Diabetes, 15(3), pp.158~162 (2014)
  6. Ferrannini E, "Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise : a randomized, double-blind, placebo-controlled, phase 3 trial", Diabetes Care, 33(10), pp.2217~2224 (2010)
  7. Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin : a randomised, double-blind, placebo-controlled trial", Lancet, 375(9733), pp.2223~2233 (2010)
  8. Strojek K, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride : a randomized, 24-week, doubleblind, placebo-controlled trial", Diabetes Obes Metab, 13(10), pp.928~938 (2011)
  9. Wilding JP, "Longterm efficacy of dapagliflozin in patients with type2 diabetes mellitus receiving high doses of insulin: arandomized trial", Ann Intern Med, 156(6), pp.405~415 (2012)
  10. Nauck MA, "Dapagliflozin versusglipizide as add-on therapy in patients with type 2diabetes who have inadequate glycemic control withmetformin : a randomized, 52-week, double-blind, active-controlled noninferiority trial", Diabetes Care, 34(9), pp.2015~2022 (2011)
  11. Ahmadieh H, "Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus", Diabetes Technol Ther, 19(9), pp.507~512 (2017)
  12. Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions" (2019), John Wiley & Sons
  13. Cochran WG, "The combination of estimates from different experiments", Biometrics, 10(1), pp.101~109 (1954)
  14. Begg CB, "Operating characteristics of a rank correlation test for publication bias", Biometrics, 50(4), pp.1088~1101 (1994)
  15. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315(7109), pp.629~634 (1997)
  16. Balasubramanian P, "Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?", J Clin Endocrinol Metab, 107(7), pp.e3003~e3007 (2022)
  17. Ferreira JP, "Empagliflozin and uric acid metabolism in diabetes : A post hoc analysis of the EMPA-REG OUTCOME trial", Diabetes Obes Metab, 24(1), pp.135~141 (2022)
  18. Mordi NA, "Renal and Cardiovascular Effects of SGLT2Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure : The RECEDE-CHF Trial", Circulation, 142(18), pp.1713~1724 (2020)
  19. Fuchigami A, "Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes : a prospective, randomized study(DIVERSITY-CVR)", Cardiovasc Diabetol, 19(1), pp.1~ (2020)
  20. Yang W, "Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs : A randomized controlled trial", J Diabetes, 10(7), pp.589~599 (2018)
  21. Yale JF, "Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks : A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus", Clin Ther, 39(11), pp.2230~2242 (2017)[DOI]
  22. Yang W, "Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure : A randomized controlled trial", J Diabetes, 8(6), pp.796~808 (2016)
  23. Haneda M, "Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus", Clin Ther, 38(1), pp.66~88 (2016)[DOI]
  24. Nauck MA, "Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin", Diabetes Obes Metab, 16(11), pp.1111~1120 (2014)
  25. Yip ASY, "Effect of sodium-glucose cotransporter-2 (SG LT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials", Ther Adv Chronic Dis, 13 (2022)
  26. Banerjee M, "Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout : A meta-analysis and meta-regression of randomized controlled trials", Diabetes Obes Metab, 25(9), pp.2697~2703 (2023)
  27. Pawlos A, "Neuroprotective Effect of SGLT2 Inhibitors", Molecules, 26(23), pp.7213~ (2021)
  28. Mancinetti F, "Diabetes-Alzheimer’s connection in older age: SGLT2 inhibitors as promising modulators of disease pathways", Ageing Res Rev, 90, pp.102018~ (2023)
  29. Kaneto H, "Unexpected pleiotropic effects of SGLT2inhibitors : pearls and pitfalls of this novel antidiabetic class", Int J Mol Sci, 22(6), pp.3062~ (2021)
  30. Dong B, "The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture", Front Endocrinol(Lausanne), 13, pp.918350~ (2022)
  31. Wang X, "Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus : a systematic review and meta-analysis", Osteoporos Int (2023)

이 간행물의 다른 논문 (3건)

환자가 인식한 병원약사의 환자중심성 커뮤니케이션, 신뢰 및 만족도홍지승, 조윤숙, 전아영, 김가현, 김성환, 김현정, 이유미, 최정윤, 이하연, 도지현, 오헤리, 최나이, 진혜경, 이옥상, 김아정, 서성연pp. 387-408노인의료센터 입원 환자 중 약물관련문제로 인한 입원의 유병률 및 위험인자 분석김은경, 최정연, 이주연, 김광일, 노주현, 김다혜, 박소연, 김윤희, 남궁형욱, 이정화, 김서영pp. 409-422Lacosamide 정맥 주사 후 발생한 심박동 및 심전도 이상 발생 분석최경숙, 조정원, 김건희, 김민경, 김은경, 이주연, 이정화pp. 433-448
원문 보기